Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEON NASDAQ:APVO NASDAQ:KZIA NASDAQ:QNCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.93+2.5%$1.02$0.45▼$1.45$23.61M0.66139,768 shs19,873 shsAPVOAptevo Therapeutics$5.00+2.9%$5.07$3.80▼$258.01$5.90M1.64132,835 shs5,703 shsKZIANovogen$14.05+4.7%$9.24$3.19▼$17.40$23.30M2.22222,400 shs86,137 shsQNCXQuince Therapeutics$1.25-4.2%$1.16$0.80▼$45.50$20.38M1.457.52 million shs138,771 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma+0.61%-0.44%-2.88%-17.18%+89.83%APVOAptevo Therapeutics-1.62%+0.21%+16.55%-27.46%-96.49%KZIANovogen-3.11%-1.69%+39.40%+131.61%+311.98%QNCXQuince Therapeutics+6.56%-0.76%-20.25%-6.54%-87.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.93+2.5%$1.02$0.45▼$1.45$23.61M0.66139,768 shs19,873 shsAPVOAptevo Therapeutics$5.00+2.9%$5.07$3.80▼$258.01$5.90M1.64132,835 shs5,703 shsKZIANovogen$14.05+4.7%$9.24$3.19▼$17.40$23.30M2.22222,400 shs86,137 shsQNCXQuince Therapeutics$1.25-4.2%$1.16$0.80▼$45.50$20.38M1.457.52 million shs138,771 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma+0.61%-0.44%-2.88%-17.18%+89.83%APVOAptevo Therapeutics-1.62%+0.21%+16.55%-27.46%-96.49%KZIANovogen-3.11%-1.69%+39.40%+131.61%+311.98%QNCXQuince Therapeutics+6.56%-0.76%-20.25%-6.54%-87.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEONAEON Biopharma 3.00BuyN/AN/AAPVOAptevo Therapeutics 2.33HoldN/AN/AKZIANovogen 2.50Moderate Buy$21.0049.51% UpsideQNCXQuince Therapeutics 1.71Reduce$65.005,120.88% UpsideCurrent Analyst Ratings BreakdownLatest APVO, AEON, KZIA, and QNCX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026QNCXQuince Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/24/2026APVOAptevo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/21/2026KZIANovogen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026KZIANovogen LaidlawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$25.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEONAEON BiopharmaN/AN/AN/AN/A($4.12) per shareN/AAPVOAptevo TherapeuticsN/AN/AN/AN/A$17.42 per shareN/AKZIANovogen$30K772.53N/AN/A($5.34) per share-2.63QNCXQuince TherapeuticsN/AN/AN/AN/A($6.41) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEONAEON Biopharma-$36.63M-$2.435.18N/AN/AN/AN/A-994.63%5/20/2026 (Estimated)APVOAptevo Therapeutics-$25.97M-$1,770.33N/AN/AN/AN/A-260.82%-132.90%5/21/2026 (Estimated)KZIANovogen-$13.41MN/AN/AN/AN/AN/AN/AN/AN/AQNCXQuince Therapeutics-$83.98M-$16.90N/AN/AN/AN/A-372.88%-62.36%5/13/2026 (Estimated)Latest APVO, AEON, KZIA, and QNCX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026N/AAPVOAptevo Therapeutics-$5.60N/AN/AN/AN/AN/A5/20/2026N/AAEONAEON Biopharma-$0.44N/AN/AN/AN/AN/A5/13/2026Q1 2026QNCXQuince Therapeutics-$1.5580N/AN/AN/AN/AN/A3/26/2026Q4 2025APVOAptevo Therapeutics-$8.10$118.23+$126.33$118.23N/AN/A3/19/2026Q2 2026KZIANovogenN/A-$1.34N/A-$1.34N/AN/A2/14/2026Q2 2026KZIANovogenN/A-$1.34N/A-$1.34N/A$4.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAEONAEON BiopharmaN/AN/AN/AN/AN/AAPVOAptevo TherapeuticsN/AN/AN/AN/AN/AKZIANovogenN/AN/AN/AN/AN/AQNCXQuince TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEONAEON BiopharmaN/A0.220.22APVOAptevo TherapeuticsN/A3.823.82KZIANovogenN/A2.87N/AQNCXQuince TherapeuticsN/A0.530.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEONAEON Biopharma22.78%APVOAptevo Therapeutics8.06%KZIANovogen30.89%QNCXQuince Therapeutics30.75%Insider OwnershipCompanyInsider OwnershipAEONAEON Biopharma0.90%APVOAptevo Therapeutics0.08%KZIANovogen1.00%QNCXQuince Therapeutics20.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEONAEON Biopharma525.30 million74.37 millionNot OptionableAPVOAptevo Therapeutics501.18 million1.18 millionNot OptionableKZIANovogen121.65 million1.64 millionNo DataQNCXQuince Therapeutics6016.30 million12.99 millionOptionableAPVO, AEON, KZIA, and QNCX HeadlinesRecent News About These CompaniesQuince Therapeutics (QNCX) price target increased by 900.00% to 40.80April 28, 2026 | msn.comQuince Therapeutics Delays Annual 10-K FilingApril 27, 2026 | theglobeandmail.comQuince Therapeutics settles $16.4M debt with $5.5M paymentMarch 30, 2026 | msn.comWhy did QNCX stock surge 40% in pre-market today?March 30, 2026 | msn.comQuince Therapeutics Settles Approximately $16.4 Million of DebtMarch 30, 2026 | businesswire.comBankruptcy threat looms as Quince runs out of optionsFebruary 13, 2026 | pharmaphorum.comPQuince Therapeutics stock plummets after revealing strategic alternativesFebruary 13, 2026 | au.investing.comQuince Therapeutics (QNCX) Stock Erupts 300% as Buyout Rumors EmergeFebruary 11, 2026 | blockonomi.comQuince Therapeutics stock soars after engaging LifeSci Capital as advisorFebruary 10, 2026 | au.investing.comWhy is QNCX stock up 60% pre-market after a near-total wipeout?February 10, 2026 | msn.comQuince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic AlternativesFebruary 9, 2026 | businesswire.comPolaryx Therapeutics, Inc. Strengthens Board of Directors with New Appointments as Company Advances to Phase 2 TrialFebruary 5, 2026 | quiverquant.comQQuince Therapeutics Announces Significant Board of Directors ResignationsFebruary 4, 2026 | theglobeandmail.comQuince Therapeutics (QNCX) price target decreased by 21.74% to 6.12February 4, 2026 | msn.comQuince stock plunges 95% following failed clinical trial for inherited childhood diseaseFebruary 2, 2026 | bizjournals.comQuince Therapeutics on the brink as steroid-in-blood-cell fails in rare genetic diseaseJanuary 31, 2026 | fiercepharma.comFCitizens downgrades Quince Therapeutics (QNCX)January 31, 2026 | msn.comWhy Quince Therapeutics, Inc.’s (QNCX) Stock Is Down 29.66%January 31, 2026 | aaii.comAQuince Therapeutics stock tumbles after failed Phase 3 trial resultsJanuary 29, 2026 | in.investing.comQuince Ends Development of Lead Drug Candidate; Shares SlideJanuary 29, 2026 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPVO, AEON, KZIA, and QNCX Company DescriptionsAEON Biopharma NASDAQ:AEON$0.93 +0.02 (+2.53%) As of 11:28 AM Eastern This is a fair market value price provided by Massive. Learn more.AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.Aptevo Therapeutics NASDAQ:APVO$5.00 +0.14 (+2.88%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Novogen NASDAQ:KZIA$14.05 +0.64 (+4.74%) As of 11:28 AM Eastern This is a fair market value price provided by Massive. Learn more.Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.Quince Therapeutics NASDAQ:QNCX$1.25 -0.06 (-4.23%) As of 11:28 AM Eastern This is a fair market value price provided by Massive. Learn more.Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
